A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: A prospective randomised phase III study

European Journal of Cancer

Volumn 40, Issue 8, 2004, Pages 1159-1169

  Van Agthoven, M ^a   Segeren, C M ^b   Buijt, I ^a   Uyl De Groot, C A ^a   Van Der Holt, B ^a   Lokhorst, H M ^c   Sonneveld, P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Costs and cost analysis; Intensive chemotherapy; Interferon; Melphalan; Multiple myeloma; Myeloablative therapy; Stem cell rescue; Transplantation, autologous

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MYELOABLATIVE AGENT; VINCRISTINE;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COST UTILITY ANALYSIS; DRUG DOSE REGIMEN; ECONOMIC EVALUATION; FOLLOW UP; HUMAN; MEDICAL INFORMATION; MEDICAL RECORD; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 1942424107     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.01.019     Document Type: Article

References (43)

1. Alexanian R., Haut A., Khan A.U.et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 208:1969;1680-1685.
2. Alexanian R., Barlogie B., Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am. J. Hematol. 33:1990;86-89.
3. Alexanian R., Dimopoulos M. The treatment of multiple myeloma. N. Engl. J. Med. 330:1994;484-489.
4. Sporn J.R., McIntyre O.R. Chemotherapy of previously untreated multiple myeloma patients. an analysis of recent treatment results Semin. Oncol. 13:1986;318-325.
5. Bergsagel D.E. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? Eur. J. Cancer Clin. Oncol. 25:1989;159-161.
6. Tsuchiya J., Murakami H., Kanoh T.et al. Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group. Br. J. Haematol. 87:1994;832-834.
7. McElwain T.J., Powles R.L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 2:1983;822-824.
8. Selby P.J., McElwain T.J., Nandi A.C.et al. Multiple myeloma treated with high dose intravenous melphalan. Br. J. Haematol. 66:1987;55-62.
9. Attal M., Harousseau J.L., Stoppa A.M.et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335:1996;91-97.
10. Child J.A., Morgan G.J., Davies F.E.et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348:2003;1875-1883.
11. Segeren C.M., Sonneveld P., van der Holt B.et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma. a prospective randomized phase 3 study Blood. 101:2003;2144-2151.
12. Sampson F.C., Beard S.M., Scott F., Vandenberghe E. Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. Br. J. Haematol. 113:2001;1015-1019.
13. Drummond M.F., O'Brien B.J., Stoddart G.L., Torrance G.W. Methods for the economic evaluation of health care programs. 1997;Oxford University Press, New York.
14. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 36:1975;842-854.
15. Segeren C.M., Sonneveld P., van der Holt B.et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br. J. Haematol. 105:1999;127-130.
16. Lokhorst H.M., Sonneveld P., Wijermans P.W.et al. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma. Br. J. Haematol. 92:1996;44-48.
17. Horngren C.T., Foster G. Cost Accounting: A Managerial Emphasis. 2000;Prentice-Hall, New Jersey.
18. Oostenbrink J.B., Koopmanschap M.A., Rutten F.F.H. Manual for Costing Research (in Dutch). 2000;Health Care Board, Amstelveen.
19. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-effectiveness in Health and Medicine. 1996;Oxford University Press, New York.
20. van der Kuy A. Pharmacotherapeutical Compass 2000/2001 (in Dutch). 2000;Health Care Board, Amstelveen.
21. Oostenbrink J.B., Buijs-Van der Woude T., van Agthoven M., Koopmanschap M.A., Rutten F.F. Unit costs of inpatient hospital days. Pharmacoeconomics. 21:2003;263-271.
22. Segeren C.M. Intensive Therapy in Multiple Myeloma. 2002;Erasmus University, Rotterdam. (Thesis).
23. EuroQol Group EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 16:1990;199-208.
24. Dolan P. Modeling valuations for EuroQol health states. Med. Care. 35:1997;1095-1108.
25. Stolk E.A., Poley M.J., Brouwer W.B.F., van Busschbach J.J. Testing the iMTA-model. Identification of disorders with minimal burden of disease, and testing of the efficiency test corrected for burden of disease. Supplemental Study of the Scope of the Drug Reimbursement System. 2002;Health Care Insurance Board, Amstelveen.
26. Mathers C, Vos T, Stevenson C. The Burden of Disease and Injury in Australia. Canberra, 1999.
27. Riteco J.A., de Heij L.J.M., van Luijn J.C.F., Wolff I. Guidelines for Pharmacoeconomic Research (in Dutch). 1999;Health Care Insurance Board, Amstelveen.
28. Severens J.L., De Boo T.M., Konst E.M. Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals. Int. J. Technol. Assess Health Care. 15:1999;608-614.
29. Barber J.A., Thompson S.G. Analysis of cost data in randomized trials. an application of the non-parametric bootstrap Stat. Med. 19:2000;3219-3236.
30. Briggs A., Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 7:1998;723-740.
31. Chaudhary M.A., Stearns S.C. Estimating confidence intervals for cost-effectiveness ratios. an example from a randomized trial Stat. Med. 15:1996;1447-1458.
32. Goldschmidt H., Hegenbart U., Wallmeier M.et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann. Oncol. 8:1997;243-246.
33. Lahuerta J.J., Martinez-Lopez J., Grande C.et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma. a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma Br. J. Haematol. 109:2000;138-147.
34. Duncan N., Hewetson M., Powles R., Raje N., Mehta J. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant. 18:1996;1175-1178.
35. Ager S., Scott M.A., Mahendra P.et al. Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma. a retrospective comparison with autologous bone marrow transplantation Bone Marrow Transplant. 16:1995;79-83.
36. Jagannath S., Vesole D.H., Zhang M.et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant. 20:1997;445-450.
37. Morabito F., Martino M., Stelitano C.et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica. 87:2002;1192-1199.
38. Coyte P.C., Dobrow M.J., Broadfield L. Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma. Pharmacoeconomics. 19:2001;845-854.
39. Henon P., Donatini B., Eisenmann J.C., Becker M., Beck-Wirth G. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma. Bone Marrow Transplant. 16:1995;19-25.
40. Johnson P.W., Simnett S.J., Sweetenham J.W., Morgan G.J., Stewart L.A. Bone marrow and peripheral blood stem cell transplantation for malignancy. Health Technol. Assess. 2:1998;1-187.
41. Gulbrandsen N., Wisloff F., Nord E., Lenhoff S., Hjorth M., Westin J. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur. J. Haematol. 66:2001;328-336.
42. Wisloff F., Gulbrandsen N., Nord E. Therapeutic options in the treatment of multiple myeloma. pharmacoeconomic and quality-of-life considerations Pharmacoeconomics. 16:1999;329-341.
43. Sirohi B., Powles R., Treleaven J.et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 25:2000;533-539.